Metastatic Cancer

On August 15, 2019, the FDA granted accelerated approval to entrectinib (Rozlytrek; Genentech) for the treatment of patients aged ≥12 years with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have progressed after treatment or have no satisfactory standard therapy.

Read More ›

Two cancer experts at Johns Hopkins Kimmel Cancer Center in Baltimore, MD, are advocating for greater focus on metastatic cancer survivorship and its impact on those living with incurable cancer, a situation they know all too well. Both are living with metastatic cancer and are urging the medical community to increase the study and awareness of this condition and improve the lives of this growing population. Read More ›

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: